ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY
- Written by: PR Newswire Asia - News Pronto RSS
 |
PARIS, May 17, 2022 /PRNewswire/ -- ABL Europe (ABL), a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine candidates, gene and cancer therapies and Odimma Therapeutics (Odimma) a young biotechnological company focusing on personalized cancer immunotherapy,...
Read more: ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY